Recent News

• 06.04.2026 - Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
• 06.03.2026 - Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
• 06.01.2026 - Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
• 05.27.2026 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 05.26.2026 - Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
• 05.07.2026 - Axsome Therapeutics Recognizes Mental Health Month
• 05.05.2026 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 05.04.2026 - Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Recent Filings

• 06.03.2026 - EX-99.1 EX-99.1
• 06.03.2026 - 8-K Current report
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 144 Report of proposed sale of securities
• 06.01.2026 - 144 Report of proposed sale of securities
• 05.29.2026 - 144 Report of proposed sale of securities
• 05.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.05.2026 - 144/A Report of proposed sale of securities
• 05.05.2026 - 144 Report of proposed sale of securities
• 05.04.2026 - EX-99.1 EX-99.1